Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania.

Periclou A, Willavize S, Jaworowicz D, Passarell J, Carrothers T, Ghahramani P, Durgam S, Earley W, Kapás M, Khariton T.

Clin Transl Sci. 2020 Mar;13(2):362-371. doi: 10.1111/cts.12720. Epub 2019 Dec 27.

2.

Expression of transforming growth factor-beta and interferon gamma biomarkers after whole body gamma irradiation.

Fardid R, Ghahramani P, Mosleh-Shirazi MA, Kalantari T, Behzad-Behbahani A, Kazemi E, Okhovat MA.

J Cancer Res Ther. 2019 Mar;15(Supplement):S135-S139. doi: 10.4103/jcrt.JCRT_1324_16.

3.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

4.

Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.

Chen L, Boinpally R, Gad N, Greenberg WM, Wangsa J, Periclou A, Ghahramani P.

Clin Drug Investig. 2015 Oct;35(10):601-12. doi: 10.1007/s40261-015-0318-2.

PMID:
26315684
5.

Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.

Chen L, Greenberg WM, Gommoll C, O'Connor J, Zukin SR, Periclou A, Ghahramani P.

Clin Ther. 2015 Sep;37(9):2059-70. doi: 10.1016/j.clinthera.2015.07.005. Epub 2015 Aug 20.

PMID:
26256429
6.

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.

Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P.

Drug Des Devel Ther. 2015 Jun 25;9:3293-300. doi: 10.2147/DDDT.S85418. eCollection 2015.

7.

A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.

Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P.

Am J Ther. 2015 Sep-Oct;22(5):e130-40. doi: 10.1097/MJT.0000000000000247.

8.

Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.

Chen L, Boinpally R, Greenberg WM, Wangsa J, Periclou A, Ghahramani P.

Clin Drug Investig. 2014 May;34(5):351-9. doi: 10.1007/s40261-014-0182-5.

PMID:
24677141
9.

Male reproductive health under threat: Short term exposure to radiofrequency radiations emitted by common mobile jammers.

Mortazavi S, Parsanezhad M, Kazempour M, Ghahramani P, Mortazavi A, Davari M.

J Hum Reprod Sci. 2013 Apr;6(2):124-8. doi: 10.4103/0974-1208.117178.

10.

Clinical relevance of dissolution testing in quality by design.

Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, Hammett T, Billett L, Behn S, Gibb RC, Abrahamsson B.

AAPS J. 2008 Jun;10(2):380-90. doi: 10.1208/s12248-008-9034-7. Epub 2008 Aug 7. Review.

11.

PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.

Davies SJ, Lennard MS, Ghahramani P, Pratt P, Robertson A, Potokar J.

J Psychopharmacol. 2007 Mar;21(2):153-60. Erratum in: J Psychopharmacol. 2008 Aug;22(6):698.

PMID:
17329294
12.

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P.

J Clin Oncol. 2005 Apr 1;23(10):2162-71.

PMID:
15800309
13.

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V.

Ann Oncol. 2004 Jan;15(1):19-27.

14.

Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:37-44.

15.

No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D.

Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:30-6.

16.

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P.

J Clin Oncol. 2003 Nov 1;21(21):3965-71. Epub 2003 Sep 24.

PMID:
14507946
17.

No evidence that panic attacks are associated with the white coat effect in hypertension.

Davies SJ, Jackson PR, Ramsay LE, Ghahramani P, Palmer RL, Hippisley-Cox J.

J Clin Hypertens (Greenwich). 2003 Mar-Apr;5(2):145-52.

18.

Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients.

Davies SJ, Jackson PR, Ramsay LE, Ghahramani P.

Arch Intern Med. 2003 Mar 10;163(5):592-600.

PMID:
12622606
19.

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D.

Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53.

20.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR.

Pediatr Infect Dis J. 2002 Mar;21(3):240-8.

PMID:
12005089
21.

Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation.

Wallis EJ, Ramsay LE, Haq IU, Ghahramani P, Jackson PR.

J Hypertens. 2001 Apr;19(4):691-6.

PMID:
11330871
22.
23.

Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cells.

Chong LK, Chowdry J, Ghahramani P, Peachell PT.

Pharmacogenetics. 2000 Mar;10(2):153-62.

PMID:
10762003
24.

Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW.

BMJ. 2000 Mar 11;320(7236):671-6. Erratum in: BMJ 2000 Apr 15;320(7241):1034.

25.

Association of panic disorder and panic attacks with hypertension.

Davies SJ, Ghahramani P, Jackson PR, Noble TW, Hardy PG, Hippisley-Cox J, Yeo WW, Ramsay LE.

Am J Med. 1999 Oct;107(4):310-6.

PMID:
10527031
26.

Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells.

Drury DE, Chong LK, Ghahramani P, Peachell PT.

Br J Pharmacol. 1998 Jun;124(4):711-8.

27.

Protein binding of aspirin and salicylate measured by in vivo ultrafiltration.

Ghahramani P, Rowland-Yeo K, Yeo WW, Jackson PR, Ramsay LE.

Clin Pharmacol Ther. 1998 Mar;63(3):285-95.

PMID:
9542472
28.

Panic disorder, anxiety and depression in resistant hypertension--a case-control study.

Davies SJ, Ghahramani P, Jackson PR, Hippisley-Cox J, Yeo WW, Ramsay LE.

J Hypertens. 1997 Oct;15(10):1077-82.

PMID:
9350581
29.

Protection by dexamethasone of the functional desensitization to beta 2-adrenoceptor-mediated responses in human lung mast cells.

Chong LK, Drury DE, Dummer JF, Ghahramani P, Schleimer RP, Peachell PT.

Br J Pharmacol. 1997 Jun;121(4):717-22.

30.

Cytochromes P450 mediating the N-demethylation of amitriptyline.

Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT.

Br J Clin Pharmacol. 1997 Feb;43(2):137-44.

31.

Supplemental Content

Loading ...
Support Center